Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
October 6, 2003
- 1st Drug Therapy for Internal Hemorrhoids Expected in FY2004: Lequio, MPC
October 6, 2003
- Takara Bio Develops High Precision Monitoring Method for Inserted Genes
October 6, 2003
- PBI to Begin Full-scale Contract Manufacture of Antibody Drugs
October 6, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 6, 2003
- WORLD NEWS IN BRIEF
September 29, 2003
- PRESS SEMINAR
September 29, 2003
- Boosting Awareness of Migraine Key to Maxalt Promotion: Eisai
September 29, 2003
- JACDS Proposes OTC Drug Reclassification for Sales Deregulation
September 29, 2003
- Banyu to Provide Tailor-made Evidence to Boost Nu-lotan
September 29, 2003
- Free OTC Drugs Supply via Videophone Violates PAL?
September 29, 2003
- Sales of Uralyt Could Triple to \10 Bil.: Nippon Chemiphar
September 29, 2003
- OTC NEWS IN BRIEF
September 29, 2003
- Mochida to Transfer All Ethical Drug Formulation to Otawara Plant
September 29, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 29, 2003
- Leading SMOs Prefer Experience in Hiring: PJ Survey
September 29, 2003
- DIAGNOSTIC NEWS IN BRIEF
September 29, 2003
- RAD-AR Council Hosts Symposium for Public and Pharmacists
September 29, 2003
- BULLETIN
September 29, 2003
- BUSINESS NEWS IN BRIEF
September 29, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…